Abu-Hamdan D K, Mahajan S K, Migdal S, Prasad A S, McDonald F D
Department of Medicine, Wayne State University, Detroit, Michigan.
J Am Coll Nutr. 1988 Jun;7(3):235-40. doi: 10.1080/07315724.1988.10720240.
The effect of 1,25(OH)2D3 on zinc absorption was indirectly determined in hemodialysis patients using the oral zinc tolerance test. The increment in plasma zinc and the area under the curve following an oral zinc load of 25 mg were studied in seven patients, before and after 6 weeks of therapy with 1 microgram/day of 1,25(OH)2D3 [Rocaltrol(R)]. Before therapy, fasting plasma zinc, 2 hour plasma zinc, and the area under the curve (AUC) were subnormal (hemodialysis patients vs normals: 96 +/- 2 vs 105 +/- 3 micrograms/dl, p less than 0.05, 161 +/- 8 vs 222 +/- 16 micrograms/dl, p less than 0.025, and 188 +/- 25 vs 302 +/- 33 micrograms hr/dl, p less than 0.025, respectively). Following Rocaltrol, serum calcium level increased (8.9 +/- .12 to 9.8 +/- .4 mg/dl, p less than 0.05), parathyroid hormone levels decreased (20.4 +/- 8.9 to 13.6 +/- 7.2 ng/ml, p less than 0.05), but there was no significant change in fasting plasma zinc, 2 hour plasma zinc, or AUC (89 +/- 3 micrograms/dl, 149 micrograms/dl, and 176 +/- 18 micrograms hr/dl, respectively). These results suggest that short-term 1,25(OH)2D3 therapy had no significant impact on zinc absorption or plasma zinc level in uremics.
采用口服锌耐量试验间接测定了1,25(OH)₂D₃对血液透析患者锌吸收的影响。研究了7例患者在每天服用1微克1,25(OH)₂D₃[罗钙全（Rocaltrol）]治疗6周前后，口服25毫克锌负荷后血浆锌的增量及曲线下面积。治疗前，空腹血浆锌、2小时血浆锌及曲线下面积（AUC）均低于正常水平（血液透析患者与正常人相比：分别为96±2与105±3微克/分升，p＜0.05；161±8与222±16微克/分升，p＜0.025；188±25与302±33微克·小时/分升，p＜0.025）。服用罗钙全后，血清钙水平升高（8.9±0.12至9.8±0.4毫克/分升，p＜0.05），甲状旁腺激素水平降低（20.4±8.9至13.6±7.2纳克/毫升，p＜0.05），但空腹血浆锌、2小时血浆锌或AUC无显著变化（分别为89±3微克/分升、149微克/分升和176±18微克·小时/分升）。这些结果表明，短期1,25(OH)₂D₃治疗对尿毒症患者的锌吸收或血浆锌水平无显著影响。
